Literature DB >> 23868031

Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Enikő Orosz1, István Ember, Katalin Gombos, László Tóth, Ádám Tarpay, Ákos Pap, Szabolcs Ottó.   

Abstract

Early diagnosis of recurrence and metastasis of colorectal cancer following surgery of curative intent is of vital importance in terms of survival and quality of life. The consistent implementation of appropriate patient follow-up strategy is therefore essential. Debates over the methodology, evaluation and strategy of follow-up have been known for many years, and continue today. By introducing several follow-up models, the present paper offers different options featuring certain individual, national and international, conceptual and financial aspects. Colorectal cancer is an important public health concern due to its destructive nature and frequency, it is therefore essential to develop new monitoring strategies, involving new biomarkers and extensive clinical validation. Since the recurrence rate is very high in high-risk patients, the improvement of individual patient risk estimates and the utilization of a corresponding follow-up model require broad international co-operation and common practice, along with the determination of optimal levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23868031     DOI: 10.1007/s12253-013-9672-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  83 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

3.  Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer.

Authors:  Sanna A Mulder; Monique E Van Leerdam; Rob J Th Ouwendijk; Dirk J Bac; Raimond W M Giard; Ernst J Kuipers
Journal:  Scand J Gastroenterol       Date:  2007-01       Impact factor: 2.423

4.  Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.

Authors:  Hajime Shibuya; Hisae Iinuma; Ryu Shimada; Atsushi Horiuchi; Toshiaki Watanabe
Journal:  Oncology       Date:  2011-03-17       Impact factor: 2.935

5.  Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities.

Authors:  Joanne Man-Wai Ho; David Nelson Juurlink; Rodrigo Brandao Cavalcanti
Journal:  Ann Pharmacother       Date:  2010-02-02       Impact factor: 3.154

6.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

7.  Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study.

Authors:  Frédéric Borie; Jean-Pierre Daurès; Bertrand Millat; Brigitte Trétarre
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

8.  Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice.

Authors:  I Grossmann; G H de Bock; C J H van de Velde; J Kievit; T Wiggers
Journal:  Colorectal Dis       Date:  2007-06-30       Impact factor: 3.788

9.  Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.

Authors:  Stephan E Baldus; Karl-L Schaefer; Rainer Engers; Dinah Hartleb; Nikolas H Stoecklein; Helmut E Gabbert
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

10.  Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients.

Authors:  I Tarantino; R Warschkow; M Worni; K Merati-Kashani; D Köberle; B M Schmied; S A Müller; T Steffen; T Cerny; U Güller
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

View more
  2 in total

1.  Defining early recurrence in patients with resected primary colorectal carcinoma and its respective risk factors.

Authors:  Felix Wiesmueller; Rolf Schuetz; Melanie Langheinrich; Maximilian Brunner; Georg F Weber; Robert Grützmann; Susanne Merkel; Christian Krautz
Journal:  Int J Colorectal Dis       Date:  2021-01-15       Impact factor: 2.571

2.  Modulation of the colon cancer cell phenotype by pro-inflammatory macrophages: A preclinical model of surgery-associated inflammation and tumor recurrence.

Authors:  María Marcuello; Xavier Mayol; Eloísa Felipe-Fumero; Jaume Costa; Laia López-Hierro; Silvia Salvans; Sandra Alonso; Marta Pascual; Luís Grande; Miguel Pera
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.